Te Ahumairangi Investment Management Ltd trimmed its position in Pfizer Inc. (NYSE:PFE - Free Report) by 6.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 199,423 shares of the biopharmaceutical company's stock after selling 13,200 shares during the quarter. Pfizer comprises 1.1% of Te Ahumairangi Investment Management Ltd's holdings, making the stock its 28th largest position. Te Ahumairangi Investment Management Ltd's holdings in Pfizer were worth $5,291,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Retirement Wealth Solutions LLC purchased a new stake in Pfizer in the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the fourth quarter worth $28,000. Noble Wealth Management PBC acquired a new stake in Pfizer during the fourth quarter valued at $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer in the fourth quarter valued at $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.
Pfizer Trading Up 0.8 %
Shares of NYSE:PFE traded up $0.19 during mid-day trading on Wednesday, reaching $24.73. 41,783,008 shares of the company were exchanged, compared to its average volume of 39,243,727. Pfizer Inc. has a 1 year low of $24.33 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm's 50-day simple moving average is $25.98 and its 200 day simple moving average is $26.83. The firm has a market cap of $140.26 billion, a price-to-earnings ratio of 17.54, a P/E/G ratio of 0.64 and a beta of 0.61.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business's quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.10 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.
Insider Transactions at Pfizer
In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The shares were bought at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company's stock.
Analyst Upgrades and Downgrades
PFE has been the topic of several recent analyst reports. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 8th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. Finally, Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $31.92.
Check Out Our Latest Stock Analysis on PFE
Pfizer Company Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
